The agenda for the 17 December 2014 Transparency Commission meeting is now available. The Commission will consider the following medicines:

• Vortioxetine hydrobromide (Brintellix) - new medicine
• Amlodipine besylate with perindopril arginine and indapamaide hemihydrate (Triplixam) - new combination product
• Abacavir sulfate with dolutegravir sodium and lamivudine (Triumeq) - new combination product
• Lixisenatide (Lyxumia) - new medicine
• Cholic acid (Kolbam) - new formulation
• Omalizumab (Xolair)  - new indication

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-12/odj_ct_17122014_internet.pdf [French]